In part 2 , for the panitumumab plus rilotumumab ( n = 48 ) , panitumumab plus ganitumab ( n = 46 ) , and panitumumab plus placebo arms ( n = 48 ) , the ORRs were 31 % , 22 % , and 21 % , respectively .